This product is human granulocyte colony-stimulating factor (rhGCSF) produced by genetic recombination technology. It is one of the main cytokines regulating granulocyte hematopoiesis in the bone marrow. It selectively acts on granulocyte hematopoietic progenitor cells, promotes their proliferation and differentiation, and can increase the function of terminally differentiated granulocyte cells.

This product is a platelet-promoting growth factor produced by genetic recombination technology. It can directly stimulate the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, induce the maturation and differentiation of megakaryocytes, increase the production of platelets in the body, thereby increasing the platelet count in the blood, while there is no significant change in platelet function. Preclinical studies have shown that after the use of this product in vivo, the mature megakaryocytes are completely normal in ultrastructure, and the morphology, function and lifespan of the generated platelets are also normal.

This product is a platelet-promoting growth factor produced by genetic recombination technology. It can directly stimulate the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, induce the maturation and differentiation of megakaryocytes, increase the production of platelets in the body, thereby increasing the platelet count in the blood, while there is no significant change in platelet function. Preclinical studies have shown that after the use of this product in vivo, the mature megakaryocytes are completely normal in ultrastructure, and the morphology, function and lifespan of the generated platelets are also normal.

This product is a platelet-promoting growth factor produced by genetic recombination technology. It can directly stimulate the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, induce the maturation and differentiation of megakaryocytes, increase the production of platelets in the body, thereby increasing the platelet count in the blood, while there is no significant change in platelet function. Preclinical studies have shown that after the use of this product in vivo, the mature megakaryocytes are completely normal in ultrastructure, and the morphology, function and lifespan of the generated platelets are also normal.

It has antithrombin III (ATⅢ)-dependent anti-factor Xa activity, and has inhibitory effects on the formation of thrombi in vivo and in vitro, and arterial and venous thrombi; it can stimulate endothelial cells to release tissue factor coagulation pathway inhibitor and plasminogen activator; when affecting coagulation function, the APTT is slightly prolonged; it is not used as a thrombolytic drug, but has an indirect synergistic effect on thrombolytic drugs; when producing antithrombotic effects, the possibility of bleeding is small; it has no mutagenic effect and does not affect reproductive function and embryonic development.